Literature DB >> 26174968

Incidence and Predictors of Multiple Fractures Despite High Adherence to Oral Bisphosphonates: A Binational Population-Based Cohort Study.

Samuel Hawley1, M Kassim Javaid1,2, Katrine H Rubin3, Andrew Judge1,2, Nigel K Arden1,2, Peter Vestergaard4, Richard Eastell5, Adolfo Diez-Perez6, Cyrus Cooper1,2, Bo Abrahamsen3,7, Daniel Prieto-Alhambra1,2,6,8.   

Abstract

Oral bisphosphonates (BPs) are highly effective in preventing fractures and are recommended first-line therapies for patients with osteoporosis. We identified the incidence and predictors of oral BP treatment failure, defined as the incidence of two or more fractures while on treatment (≥2 FWOT) among users with high adherence. Fractures were considered from 6 months after treatment initiation and up to 6 months after discontinuation. Data from computerized records and pharmacy invoices were obtained from Sistema d'Informació per al Desenvolupament de l'Investigació en Atenció Primària (SIDIAP; Catalonia, Spain) and Danish Health Registries (Denmark) for all incident users of oral BPs in 2006-2007 and 2000-2001, respectively. Fine and Gray survival models using backward-stepwise selection (p-entry 0.049; p- exit 0.10) and accounting for the competing risk of therapy cessation were used to identify predictors of ≥2 FWOT among patients having persisted with treatment ≥6 months with overall medication possession ratio (MPR) ≥80%. Incidence of ≥2 FWOT was 2.4 (95% confidence interval [CI], 1.8 to 3.2) and 1.7 (95% CI, 1.2 to 2.2) per 1000 patient-years (PYs) within Catalonia and Denmark, respectively. Older age was predictive of ≥2 FWOT in both Catalonian and Danish cohorts: subhazard ratio (SHR) = 2.28 (95% CI, 1.11 to 4.68) and SHR = 2.61 (95% CI, 0.98 to 6.95), respectively, for 65 to <80 years; and SHR = 3.19 (95% CI, 1.33 to 7.69) and SHR = 4.88 (95% CI, 1.74 to 13.7), respectively, for ≥80 years. Further significant predictors of ≥2 FWOT identified within only one cohort were dementia, SHR = 4.46 (95% CI, 1.02 to 19.4) (SIDIAP); and history of recent or older fracture, SHR = 3.40 (95% CI, 1.50 to 7.68) and SHR = 2.08 (95% CI: 1.04-4.15), respectively (Denmark). Even among highly adherent users of oral BP therapy, a minority sustain multiple fractures while on treatment. Older age was predictive of increased risk within both study populations, as was history of recent/old fracture and dementia within one but not both populations. Additional and/or alternative strategies should be investigated for these patients.
© 2015 American Society for Bone and Mineral Research.

Entities:  

Keywords:  BISPHOSPHONATES; EPIDEMIOLOGY; FRACTURES; OSTEOPOROSIS; TREATMENT FAILURE

Mesh:

Substances:

Year:  2016        PMID: 26174968     DOI: 10.1002/jbmr.2595

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  7 in total

1.  Anti-Osteoporosis Medication Prescriptions and Incidence of Subsequent Fracture Among Primary Hip Fracture Patients in England and Wales: An Interrupted Time-Series Analysis.

Authors:  Samuel Hawley; Jose Leal; Antonella Delmestri; Daniel Prieto-Alhambra; Nigel K Arden; Cyrus Cooper; M Kassim Javaid; Andrew Judge
Journal:  J Bone Miner Res       Date:  2016-07-04       Impact factor: 6.741

2.  Dried plum diet protects from bone loss caused by ionizing radiation.

Authors:  A-S Schreurs; Y Shirazi-Fard; M Shahnazari; J S Alwood; T A Truong; C G T Tahimic; C L Limoli; N D Turner; B Halloran; R K Globus
Journal:  Sci Rep       Date:  2016-02-11       Impact factor: 4.379

3.  Spanish consensus on treat to target for osteoporosis.

Authors:  X Nogués; J M Nolla; E Casado; E Jódar; M Muñoz-Torres; J M Quesada-Gómez; L Canals; M Balcells; L Lizán
Journal:  Osteoporos Int       Date:  2017-11-24       Impact factor: 4.507

4.  The limitations of using simple definitions of glucocorticoid exposure to predict fracture risk: A cohort study.

Authors:  Danielle E Robinson; Tjeerd P van Staa; Elaine M Dennison; Cyrus Cooper; William G Dixon
Journal:  Bone       Date:  2018-09-13       Impact factor: 4.398

5.  Comparison of Osteoporosis Pharmacotherapy Fracture Rates: Analysis of a MarketScan® Claims Database Cohort.

Authors:  Alan W Reynolds; Guodong Liu; Paul T Kocis; Jenna N Skowronski; Douglas L Leslie; Edward J Fox
Journal:  Int J Endocrinol Metab       Date:  2018-06-12

6.  Real-world persistence and adherence with oral bisphosphonates for osteoporosis: a systematic review.

Authors:  F Fatoye; P Smith; T Gebrye; G Yeowell
Journal:  BMJ Open       Date:  2019-04-14       Impact factor: 2.692

7.  Potential of Health Insurance Claims Data to Predict Fractures in Older Adults: A Prospective Cohort Study.

Authors:  Jonas Reinold; Malte Braitmaier; Oliver Riedel; Ulrike Haug
Journal:  Clin Epidemiol       Date:  2022-10-07       Impact factor: 5.814

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.